The first FDA-approved treatment for low sexual desire — now in a nasal spray.
You love your partner. You want to want sex. But the wanting itself has gone quiet — and no amount of the right conditions or willpower seems to bring it back. Ignite Boost Spray is prescribed for exactly this. The active ingredient Bremelanotide works in the brain, where desire actually starts, activating the neural pathways that tell your body sex play is something you want. Compared to other versions on the market, this nasal spray is perfect for folks who aren't interested in self-administering injections. Used 45 to 60 minutes before the moment, get your brain on board for pleasure again.
Size
30 mL nasal spray (30-day supply)WHAT TO EXPECT
Ignite Boost Spray is a medication used in the lead up to sex play, and is not a daily treatment. There is no cumulative build-up phase; each dose is complete in itself.
SETTING THE RIGHT EXPECTATIONS
Bremelanotide works on desire — the 'I want to want sex again'. The ingredient impacts the neural signal that initiates interest in sex play. It's important to note that it does not create arousal on its own. If stress, pain, or relationship friction are the primary drivers of low desire, with those factors as well.
45–60 MINUTES AFTER USE
After intranasal administration, bremelanotide is absorbed into the bloodstream and crosses into the central nervous system. The melanocortin receptors that govern sexual interest begin to activate. Most patients notice the shift within 45 to 60 minutes — not as a dramatic physical sensation, but as an openness or willingness that wasn't there before.
HOURS 1–6
The nasal spray formulation has an active window of approximately 4 to 6 hours. This is shorter than the injectable version, which can last 6 to 12 hours — the spray's precision is actually a feature for many patients. Blood pressure and heart rate may shift slightly during this window; this is expected and typically returns to baseline within 12 hours.
OVER TIME
Some patients find Ignite Boost Spray most valuable as a consistent on-demand tool. Others use it to reconnect with desire during a period of transition — postpartum, perimenopause, a high-stress season — and find that regular use helps them reorient toward sex play in a way that begins to feel more natural over time. Your HerTeleMeds clinician can guide you on frequency and whether the spray remains the right tool as your needs evolve.
Ignite Boost Spray is on-demand, not a daily commitment. Your HerTeleMeds clinician will help you find the cadence that fits your pattern of desire and lifestyle.
ABOUT THE TREATMENT
Most conversations about low sexual desire start in the wrong place. They start with what you're doing — or not doing — and skip right past the fact that desire is not a behavior. It is a brain event. Bremelanotide is a synthetic peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring signaling molecule in the body. When administered intranasally, it activates melanocortin receptors in the brain — specifically MC1R and MC4R — in the hypothalamus, the region that governs sexual interest and response. This is not a hormone. It is not an antidepressant. It does not act on serotonin or estrogen. It acts directly on the neural circuitry where desire is generated.
This matters because desire, as sex researcher Emily Nagoski describes it, is not a drive that builds until you act on it. For most women, desire is responsive — it emerges in the right context, when the brain's accelerator is activated and its brakes aren't overwhelming the signal. What bremelanotide does is engage the accelerator at the neurological level. It gives desire a place to arise from. Ignite Boost Spray delivers bremelanotide intranasally — one spray into each nostril before sex play. The nasal route bypasses the digestive system, allowing rapid absorption directly into the bloodstream and across the blood-brain barrier. The result is a faster, more convenient administration compared to the subcutaneous injection form (Vyleesi), with a shorter, more precise active window.
Flibanserin (Addyi) is the other FDA-approved option for HSDD — a daily oral medication that works gradually over weeks by modulating serotonin and dopamine pathways. Bremelanotide is on-demand: you use it when you want it, not as part of a daily routine. The two medications work through different mechanisms in the brain. For patients who want a responsive, as-needed tool rather than a daily commitment, Ignite is the appropriate choice. Your clinician can help you determine which is right for your pattern of desire and lifestyle.
Ignite Boost Spray is prescribed for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) — meaning desire that was once present and has decreased in a way that causes meaningful distress, and where the cause is not primarily a relationship issue, medication side effect, or other medical condition. It is appropriate for patients who feel the wanting has gone quiet, not for patients experiencing primarily physical arousal difficulty or pain. If you recognize yourself in the sentence 'I love my partner, I just never feel in the mood' — this is the medication designed for that experience.
HOW TO USE
STEP 01
Administer Ignite Boost Spray 45 to 60 minutes before you anticipate sex play. This gives the medication enough time to activate the relevant neural pathways before the moment.
STEP 02
If using for the first time, prime the pump according to your pharmacy instructions before your first dose.
STEP 03
Gently insert the tip into one nostril and press the pump to deliver one spray. Repeat in the other nostril. Breathe normally — do not sniff forcefully.
STEP 04
Do not use more than one dose within a 24-hour period. This is not a take-more-for-better-results situation — the dose is calibrated. Exceeding it increases the risk of side effects without increasing efficacy.
STEP 05
Bremelanotide activates the neural signal for desire. Context does the rest. Use this medication as part of a deliberate moment — this is not a medication that overrides context, it's one that makes you more available to it.
Dosing is calibrated and precise: one spray per nostril, no more than once per 24 hours, and no more than 8 doses per month. Your clinician will tailor frequency to your needs.
FDA-approved active ingredient. Bremelanotide is one of only two FDA-approved medications for hypoactive sexual desire disorder. Ignite Boost Spray delivers the same active ingredient as the brand-name injectable — in a nasal spray, without the needle.
On-demand, not daily. Unlike the daily pill option, Ignite is used when you want it. No daily routine, no building-up period. One dose, 45 to 60 minutes before sex play.
It starts in the brain. Bremelanotide doesn't act on blood flow or hormones. It activates melanocortin receptors in the hypothalamus — the part of the brain that governs sexual interest. This is where desire actually comes from.
Paraben-free formulation. Many intimacy-related products contain parabens — preservatives that accumulate in the body and are classified as endocrine-disrupting chemicals. Parabens mimic estrogen and have been linked to hormonal disruption, particularly concerning for women already navigating perimenopause or hormonal shifts. Ignite Boost Spray contains no parabens.
Compounded at a women-of-color owned pharmacy. Formulated and dispensed by a women-of-color owned compounding pharmacy with 35+ years of experience. Precision sexual health care, made by people who understand what's at stake.
How HerTeleMeds Works
Answer a few questions about your skin and medical history.
A U.S.-licensed provider reviews your information within 24 hours.
If prescribed, your compounded formula is made fresh and arrives discreetly — often within 2–3 days.
One application a day. Results build gradually with consistent use.
Product details
FAQ
Ignite Boost Spray is a compounded prescription nasal spray containing bremelanotide, one of only two FDA-approved active ingredients for hypoactive sexual desire disorder (HSDD) in women. It is prescribed for women with acquired, generalized low sexual desire that causes real distress — not low desire explained by a relationship issue, another medical condition, or medication side effect.
Bremelanotide is a melanocortin receptor agonist — it activates specific receptors in the hypothalamus, the part of the brain that governs sexual interest. Unlike medications that work on blood flow or hormone levels, bremelanotide acts on the neural circuit where desire is generated. Think of it as engaging the accelerator at the neurological level.
Flibanserin (the brand-name daily pill for HSDD) is taken every day and works gradually over weeks by modulating serotonin and dopamine pathways. Bremelanotide is on-demand — used 45 to 60 minutes before sex play, only when you want it. Both are FDA-approved, but they work through different mechanisms and suit different lifestyles and desire patterns. Your clinician can help you determine which is right for you.
Most patients notice an effect within 45 to 60 minutes of administration. The nasal spray formulation has an active window of approximately 4 to 6 hours, making it more time-precise than the injectable version (which can last 6 to 12 hours). The effect is not a sudden physical sensation — most women describe it as an openness or receptivity that wasn't there before.
Desire is the wanting — the neural signal that initiates interest in sex play. Arousal is the physiological response that follows — blood flow, engorgement, lubrication. Sex researcher Emily Nagoski's work documents that for most women, desire is responsive rather than spontaneous: it arises in the right context, after some arousal has already begun. Bremelanotide supports desire specifically. It is not a lubrication treatment or an arousal cream — those are different mechanisms. If both are concerns, your clinician can discuss a complementary approach.
Bremelanotide is FDA-approved for premenopausal women, and clinical trials were conducted in this population. Its use in perimenopausal or postmenopausal women is off-label. That said, many patients in perimenopause experience HSDD as a primary concern, and some clinicians prescribe bremelanotide in this context with appropriate monitoring. Renée — and anyone in that hormonal transition — should discuss with their HerTeleMeds clinician whether Ignite is appropriate alongside any hormone support they're receiving.
Parabens are preservatives found in many personal care and pharmaceutical products. They are classified as endocrine-disrupting chemicals — meaning they can interfere with hormonal signaling. Parabens mimic estrogen in the body, and research has linked chronic exposure to disruptions in female reproductive hormones. For women already navigating perimenopause, hormonal shifts, or HSDD, we did not want a formulation that adds unnecessary hormonal interference. Ignite Boost Spray is formulated without parabens.
The most common side effect is nausea, which was reported by a significant portion of patients in clinical trials. Flushing, headache, and a temporary increase in blood pressure are also possible. Most of these effects resolve within 12 hours. Starting at a lower dose and titrating up, if recommended by your clinician, may reduce nausea. Reach out to your provider if side effects are persistent or feel significant.
If you've been waiting to feel in the mood — for months, maybe longer — you're not alone, and you're not broken. Hypoactive sexual desire disorder is one of the most common and least treated conditions in women's health. Ignite Boost Spray is a prescription option that starts where desire actually starts: in the brain. Begin your consultation today.
Start Your ConsultationShips within 2–3 business days after clinician approval. Prescription included with your visit. Cancel or pause anytime.
